A 104-Week, Open-Label, Multi-Centre, Phase IIIb Study Evaluating the Effect of Treatment With Rosuvastatin 40 Mg on Atherosclerotic Disease as Measured by Intravascular Ultrasound and Quantitative Coronary Angiography in Subjects Undergoing Coronary Angiography Who Have Coronary Artery Disease

Trial Profile

A 104-Week, Open-Label, Multi-Centre, Phase IIIb Study Evaluating the Effect of Treatment With Rosuvastatin 40 Mg on Atherosclerotic Disease as Measured by Intravascular Ultrasound and Quantitative Coronary Angiography in Subjects Undergoing Coronary Angiography Who Have Coronary Artery Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Nov 2009

At a glance

  • Drugs Rosuvastatin (Primary)
  • Indications Atherosclerosis; Coronary artery disease
  • Focus Therapeutic Use
  • Acronyms ASTEROID
  • Most Recent Events

    • 12 Apr 2009 Actual end date (Nov 2005) added as reported by ClinicalTrials.gov.
    • 31 Mar 2008 Results were presented in a Late-Breaking Clinical Trial session at the 57th Annual Scientific Session of the American College of Cardiology.
    • 17 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top